AbbVie Inc. has turned heads recently with a notable uptick in stock searches. Over the last month, its shares soared by +9.2 ...

Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in th ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...

Glenmark Pharmaceuticals to close ISB 2001 transaction in September, focusing on high-margin branded products for growth.

Analysts are intrested in these 5 stocks: ( ($ABBV) ), ( ($DOW) ), ( ($KTOS) ), ( ($RKT) ) and ( ($AMAT) ). Here is a breakdown of their recent ...

The U.S. Food and Drug Administration has approved Tonix Pharmaceuticals' drug to manage pain related to a type of chronic ...

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $212.70 today based on a price of $204.94 for ABBV at the time of writing.

Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.

AbbVie Inc. is in the spotlight as Cantor Fitzgerald revises its FY2025 EPS forecast upwards. Analysts now anticipate $12.05 ...

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...